AnGes : Notice Concerning Acquisition and Cancellation of the 42nd Series of Stock Acquisition Rights
April 24, 2023 at 08:17 am
Share
April 24, 2023
Company Name: AnGes Inc.
Presentative: Ei Yamada, President & CEO
Notice Concerning Acquisition and Cancellation
of the 42nd Series of Stock Acquisition Rights
AnGes announces that on April 24, 2023, AnGes's Representative Director decided to acquire the 42nd Series of Stock Acquisition Rights issued on October 12, 2022, after suspending the exercise of all remaining Stock Acquisition Rights, and that at the Board of Directors meeting held on the same day, we resolved to cancel all acquired Stock Acquisition Rights immediately after acquisition, as described below.
1. Details of the Stock Acquisition Rights to be acquired and cancelled
(1)
Name of the Stock Acquisition Rights
AnGes Inc.
The 42nd series of stock acquisition rights
(2)
Number of Stock Acquisition Rights Issued
380,000 units
(3)
Number of Stock Acquisition Rights to be acquired
38,500 units
and cancelled
(4)
Acquisition price of the Stock Acquisition Rights
134 yen per stock acquisition right
and the total amount thereof
Total amount 5,159,000 yen
(5)
Date of acquisition and retirement of the Stock
May 9, 2023
Acquisition Rights
(6) Number of Stock Acquisition Rights remaining after
0 unit
cancelled
2. Reason for Acquisition and Cancellation of Stock Acquisition Rights
On October 12, 2022, AnGes issued these
equity warrants to fund the operations of
EmendoBio Inc., a subsidiary engaged in research and development of genome editing technology, and to strengthen AnGes's business foundation.
The minimum exercise price of the Stock Acquisition Rights was set at 124 yen, and AnGes's stock price after the issuance of the Stock Acquisition Rights remained above such minimum exercise price, resulting in the Stock Acquisition Rights being exercised and the fundraising being able to proceed. However, the exercise of the remaining number (38,500 units) of these stock acquisition rights has not progressed, as AnGes's stock price is currently below the minimum exercise price of these rights.
We have decided to acquire and cancel the remaining Stock Acquisition Rights as a result of a comprehensive review of the share price trend since the issuance of the Stock Acquisition Rights, the future capital policy of AnGes, and the future market environment.
(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.
3. Future outlook
The use of funds from the acquisition and retirement of these stock acquisition rights has not been determined at this time, and will be announced once it is determined.
The acquisition and cancellation of the Stock Acquisition Rights will not have a material impact on our consolidated financial results for the fiscal year ending December 31, 2023. If any matters arise that should be disclosed in the future, we will promptly notify you.
(Note)This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.
Attachments
Original Link
Original Document
Permalink
Disclaimer
AnGes MG Inc. published this content on 24 April 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 April 2023 07:16:03 UTC.
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.